TY - JOUR
AU - 
AB - Drugs 47 (Suppl. 2): 77, 1994 00 12-6667/94/0200-0077/$0.50/0 © Adis International Limited. All rights reserved. DRSUP3889 Prof R.J. Havel: I think we are all in agreement that there is an urgent need for more trials relating to lipid lowering and cardiovascular disease in women. Primary prevention studies are very ex­ pensive and can be protracted; therefore, clinical research should concentrate on secondary preven­ tion studies. These would provide a high incidence of outcomes to monitor, with either clinical or an­ giographic methods. Eventually, of course, these would have to be followed by primary prevention studies. With regard to the use of lipid-lowering drugs in women, I believe there are now sufficient data confirming their benefit. 
TI - Concluding Remarks
JF - Drugs
DO - 10.2165/00003495-199400472-00015
DA - 2012-10-18
UR - https://www.deepdyve.com/lp/springer-journals/concluding-remarks-5tPimJpgUZ
SP - 77
EP - 77
VL - 47
IS - 2
DP - DeepDyve
ER -